Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS approves off-label chemotherapy compendium

Executive Summary

CMS will recognize the National Comprehensive Cancer Network Drugs & Biologics Compendium as an approved reference for coverage of off-label uses of cancer drugs and biologics, the agency announces June 5. Local Medicare contractors who process claims for Part B, or physician-administered, drugs would consult the compendia when deciding whether to approve claims. CMS also announces it will formally delete from its list of recognized compendia the American Medical Association Drug Evaluations compendium, which ceased publication in 1996. The decisions represent a first step in CMS' efforts to update its compendia list; decisions in the coming weeks are expected on three other references - Gold Standard's Clinical Pharmacology and Thomson Micromedex's DrugPoints and DrugDex (1"The Pink Sheet" April 14, 2008, p. 15)

You may also be interested in...



CMS Opens Door To More Compendium Oversight In Draft White Paper

A draft white paper examining conflict of interest in the production of drug compendia appears to open the door for more oversight of the publications used for determining coverage of prescription drugs' off-label indications by Medicare and private insurers

CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July

CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

UsernamePublicRestriction

Register

PS049718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel